AI assistant
IMMUTEP LIMITED — Investor Presentation 2021
May 24, 2021
65122_rns_2021-05-24_d7376ca7-866b-4c5c-8eed-4db1de02e56e.pdf
Investor Presentation
Open in viewerOpens in your device viewer
Media Release
IMMUTEP TO PRESENT AT THE JEFFERIES VIRTUAL HEALTHCARE CONFERENCE
SYDNEY, AUSTRALIA – 25 May 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announced today that Immutep CEO Marc Voigt has been invited to participate in the Jefferies Virtual Healthcare Conference, which is taking place from June 1[st] to 4[th] .
During this virtual conference, Mr. Voigt is scheduled to conduct a corporate presentation followed by a Q&A session along with Immutep’s Chief Scientific and Medical Officer, Dr. Frederic Triebel, starting at 12:30 pm ET on June 4[th] . A live webcast of this event will be available at https://wsw.com/webcast/jeff174/immp/1858869
Further details about the Jefferies Virtual Healthcare Conference can be found at https://www.jefferies.com/IdeasAndPerspectives/Conferences/325/060821
About Immutep
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.
Further information can be found on the Company’s website www.immutep.com or by contacting:
Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS +61 (0)406 759 268; [email protected]
U.S. Media:
Tim McCarthy, LifeSci Advisors +1 (212) 915.2564; [email protected]
This announcement was authorised for release by the CEO of Immutep Limited.
Immutep Limited , Level 12, 95 Pitt Street, Sydney NSW 2000 ABN: 90 009 237 889